Alle Storys
Folgen
Keine Story von Antisoma plc mehr verpassen.

Antisoma plc

Antisoma promotes Nick Adams to Director of Business Development

London, UK (ots)

Antisoma, (LSE: ASM) the biopharmaceutical
company specialising in the development of novel anti-cancer drugs,
today announces the promotion of Mr Nicholas Adams to Director of
Business Development.
Nick will lead Antisoma's business development team, for which a
key focus remains the acquisition of new products to add to
Antisoma's pipeline. He has also been appointed to Antisoma's
Executive Committee, the group responsible for the day to day running
of Antisoma Research Ltd, the wholly owned subsidiary of Antisoma
plc.
Nick had held the position of Business Development Manager at
Antisoma since June 1999. In this role he negotiated a number of
in-licensing deals and established significant development
collaborations. He was also an important contributor to the
negotiations leading to the formation of Antisoma's development and
commercialisation alliance with Roche in November 2002.
Nick, 39, studied at the College of Law, London and holds a BSc
(Hons) in Biology from the University of Hertfordshire. Prior to
joining Antisoma he held R&D positions at Ciba-Geigy, Eisai Ltd and
Cephalon Inc.
Nick replaces Bart Wuurman, who, after five years at Antisoma,
will become Chief Executive Officer of De Novo Pharmaceuticals Ltd.
Glyn Edwards, Antisoma's CEO, said, "Nick brings invaluable
expertise and experience to his new role as Director of Business
Development and I welcome him to our senior team. I would also like
to take this opportunity to thank Bart for his excellent contribution
to the company, notably his leading role in creating our alliance
with Roche."
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. The Company
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the preclinical and
clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market.  In November 2002, Antisoma signed a ground-breaking
collaboration agreement with Roche to develop and commercialise
products from Antisoma's pipeline. Please visit www.antisoma.com for
further information.
This information is provided by RNS
       The company news service from the London Stock Exchange

Contact:

Antisoma plc
Daniel Elger
Head of Corporate Communications
Tel. +44/20/8799-8200

Financial Dynamics
Jonathan Birt
Tel. +44/20/7831-3113

Weitere Storys: Antisoma plc
Weitere Storys: Antisoma plc
  • 10.09.2003 – 08:39

    Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology

    London, UK (ots) - Antisoma plc, (LSE: ASM; Nasdaq Europe: ASOM) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has in-licensed a programme of telomerase inhibitors from Cancer Research Technology Ltd, the technology transfer arm of the charity Cancer Research UK. This programme was developed by Professor Stephen ...

  • 09.09.2003 – 08:38

    Antisoma Acquires Cytogen's Royalty Rights To R1549

    London, UK and Princeton, New Jersey USA (ots) - Antisoma plc (LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a United States-based, product-driven, oncology-focused biopharmaceutical company, today announced that Antisoma has acquired certain royalty rights to Antisoma's lead product, R1549 (formerly Pemtumomab), from Cytogen. In connection ...